公开(公告)号：WO2020178743A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051812

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K35/17 ,  A61P35/00 ,  A61P37/04 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2021019472A1

公开(公告)日：2021-02-04

申请号：PCT/IB2020/057172

申请日：2020-07-29

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  SUGATA, Kenji ,  SASO, Kayoko

IPC: C12N15/867 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a CCND1 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020178741A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051810

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566 ,  A61K31/7088 ,  A61K31/713 ,  C07K14/7051 ,  C07K14/70596 ,  C07K2319/03 ,  C07K2319/70 ,  C12N15/1138 ,  C12N15/86 ,  C12N2310/14 ,  C12N2740/13043 ,  C12N9/6494

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2021019477A1

公开(公告)日：2021-02-04

申请号：PCT/IB2020/057177

申请日：2020-07-29

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  SUGATA, Kenji ,  SASO, Kayoko

IPC: C12N15/867 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  C12N15/12 ,  C12N15/63

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MAGE-A2 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020178738A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051807

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K31/12 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2021019471A1

公开(公告)日：2021-02-04

申请号：PCT/IB2020/057171

申请日：2020-07-29

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  SUGATA, Kenji ,  SASO, Kayoko

IPC: C12N15/867 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  C12N15/12 ,  C12N15/63 ,  C12N5/0783

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020178742A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051811

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  C12N5/12 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020178740A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051809

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020194195A1

公开(公告)日：2020-10-01

申请号：PCT/IB2020/052776

申请日：2020-03-24

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61K39/00 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/85 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a tyrosinase epitope, a MAGA-A1 epitope, a MART1 epitope, a MAGE-A3 epitope, or an SSX2 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020178744A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051813

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.